When is the next results date for Biocon?

No Upcoming Board Meetings

Who are in the management team of Biocon?

As of March 2023, Biocon's management team includes Kiran Mazumdar Shaw (Chairperson), Siddharth Mittal (Managing Director & CEO), and several independent directors, overseeing the company's operations and strategy.

As of March 2023, the management team of Biocon includes the following individuals:<BR><BR>1. Kiran Mazumdar Shaw - Chairperson<BR>2. Ravi Mazumdar - Director<BR>3. Vijay Kumar Kuchroo - Independent Director<BR>4. M Damodaran - Independent Director<BR>5. Bobby Parikh - Independent Director<BR>6. Mayank Verma - Company Secretary & Compliance Officer<BR>7. Siddharth Mittal - Managing Director & CEO<BR>8. Eric Vivek Mazumdar - Director<BR>9. Naina Lal Kidwai - Independent Director<BR>10. Peter John Bains - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What is the bonus history of the Biocon?

Biocon has issued bonuses on three occasions: a 1:1 bonus on June 12, 2019, a 2:1 bonus on June 15, 2017, and another 1:1 bonus on September 11, 2008, rewarding shareholders over the years.

Biocon has a history of bonus issues that includes the following:<BR><BR>1. On June 12, 2019, Biocon announced a 1:1 bonus issue, with the record date set for June 13, 2019.<BR>2. Prior to that, on June 15, 2017, the company issued a 2:1 bonus, with the record date on June 17, 2017.<BR>3. Additionally, on September 11, 2008, Biocon had a 1:1 bonus issue, with the record date on September 12, 2008.<BR><BR>This reflects Biocon's approach to rewarding shareholders through bonus shares over the years.

Has Biocon declared dividend?

Yes, Biocon Ltd. has declared a 10% dividend, amounting to ₹0.5 per share, with an ex-date of July 5, 2024. While the company has shown mixed total returns across different periods, it recorded a total return of 36.41% over the last 2 years.

Biocon Ltd. has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.5<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -12.96%, the dividend return was 0%, resulting in a total return of -12.96%.<BR><BR>Over the past year, the price return was -0.83%, the dividend return was 0.15%, leading to a total return of -0.68%.<BR><BR>In the 2-year period, the price return was 35.59%, the dividend return was 0.82%, which resulted in a total return of 36.41%.<BR><BR>For the 3-year period, the price return was 3.4%, the dividend return was 0.80%, culminating in a total return of 4.2%.<BR><BR>In the last 4 years, the price return was -14.24%, the dividend return was 0.62%, resulting in a total return of -13.62%.<BR><BR>Over the past 5 years, the price return was -15.32%, the dividend return was 0.64%, leading to a total return of -14.68%.<BR><BR>Overall, Biocon has declared a dividend, but the total returns over various periods show a mixed performance, with significant negative returns in the shorter terms and a positive return over the 2-year period.

Who are the peers of the Biocon?

Biocon's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ipca Labs, Laurus Labs, Ajanta Pharma, and Piramal Pharma. Biocon has average management risk and growth, with a 1-year return of 8.92%, lower than most peers.

Peers: The peers of Biocon are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ipca Labs, Laurus Labs, Ajanta Pharma, and Piramal Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Cohance Life, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ipca Labs, Laurus Labs, and Piramal Pharma. Average management risk is present at Biocon and Piramal Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Ajanta Pharma, and Biocon. Average growth is noted at Ipca Labs and Laurus Labs. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Ipca Labs, Good for Torrent Pharma, Average for Laurus Labs, and Below Average for Biocon and Piramal Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ajanta Pharma has the lowest at 10.15%. Biocon's own 1-year return of 8.92% is lower than both. Additionally, the peers with negative six-month returns include Biocon, Torrent Pharma, Ajanta Pharma, and Piramal Pharma.

What does Biocon do?

Biocon Limited is India's largest biopharmaceutical company, specializing in biotechnology products and research services. As of March 2025, it reported net sales of ₹44,170 Cr and a net profit of ₹3,445 Cr, with a market cap of ₹52,777 Cr.

Overview: <BR>Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company engaged in the manufacture of biotechnology products and research services, categorized as a Large Cap in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Biocon was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and Indian entrepreneur Kiran Mazumdar-Shaw. The company has evolved significantly since its inception, with the latest quarterly results reporting net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 44,170 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 3,445 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 52,777 Cr (Large Cap) <BR><BR>Key Metrics: <BR>P/E: 55.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.13% <BR>Debt-Equity: 0.64 <BR>Return on Equity: 4.40% <BR>Price to Book: 2.41 <BR><BR>Contact Details: <BR>Address: 20th KM Hosur Road Hebbagodi, Electronic City P O Bangalore Karnataka : 560100 <BR>Tel: 91-80-28082808 <BR>Email: co.secretary@biocon.com <BR>Website: http://www.biocon.com

Who are the top shareholders of the Biocon?

The top shareholders of Biocon include Kiran Mazumdar Shaw, who holds 36.24%, followed by mutual funds at 13.82%, foreign institutional investors at 7.0%, and individual investors at 13.08%. The largest public shareholder is the LICI Ulip-Growth Fund with 4.83%.

The top shareholders of Biocon include the promoters, who hold the majority of the shares. Kiran Mazumdar Shaw is the promoter with the highest holding, owning 36.24% of the company. Additionally, mutual funds hold 13.82% of the shares across 30 schemes, while foreign institutional investors (FIIs) hold 7.0% through 296 different entities. The highest public shareholder is the LICI Ulip-Growth Fund, which holds 4.83%. Individual investors collectively own 13.08% of the shares.

How big is Biocon?

As of 24th July, Biocon Ltd. has a market capitalization of 53,860.00 Cr, with recent Net Sales of 15,261.70 Cr and a Net Profit of 1,013.30 Cr. Shareholder's Funds are 21,644.00 Cr, and Total Assets are valued at 58,539.60 Cr.

As of 24th July, Biocon Ltd. has a market capitalization of 53,860.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Biocon reported Net Sales of 15,261.70 Cr and a Net Profit of 1,013.30 Cr.<BR><BR>For the reporting period of March 2025, Biocon's Shareholder's Funds amounted to 21,644.00 Cr, while Total Assets were valued at 58,539.60 Cr.

Is Biocon overvalued or undervalued?

As of September 9, 2025, Biocon is considered overvalued with a PE ratio of 139.57, significantly higher than its peers, and despite recent stock performance outpacing the Sensex, it has declined 3.29% over the past year, indicating a shift in valuation from very attractive to attractive.

As of 9 September 2025, Biocon's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its market position. The company appears to be overvalued, with a PE ratio of 139.57, significantly higher than its peers such as Cipla at 23.28 and Dr. Reddy's Labs at 18.99, which are both categorized as attractive. Additionally, Biocon's EV to EBITDA stands at 19.15, while its PEG ratio is notably at 0.00, suggesting limited growth expectations relative to its current valuation.<BR><BR>In comparison to its peers, Biocon's financial metrics highlight a disparity; for instance, Sun Pharma has a PE ratio of 33.36, categorized as expensive, while Divi's Lab is deemed very expensive with a PE of 69.19. The company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 2.76% and 6.20%, respectively. However, the longer-term view shows a decline of 3.29% over the past year, contrasting with the Sensex's minor drop of 0.56%. This further supports the conclusion that Biocon is currently overvalued in the market.

Is Biocon technically bullish or bearish?

As of October 30, 2025, Biocon's trend has shifted to bullish with moderate strength, supported by bullish daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish MACD on the weekly chart.

As of 30 October 2025, the technical trend for Biocon has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include the daily moving averages which are bullish, and the Bollinger Bands showing bullish signals on both weekly and monthly time frames. However, the MACD on the weekly is mildly bearish, which suggests some caution. Overall, the bullish trend is supported by strong performance relative to the Sensex, particularly over the past month and year.

How has been the historical performance of Biocon?

Biocon has demonstrated consistent growth in net sales and profits, with net sales increasing from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025, and profit after tax rising from INR 1,001.70 crore to INR 1,429.40 crore during the same period, despite a slight decline in operating profit margin. Total assets grew significantly, reflecting strong overall financial performance.

Answer:<BR>The historical performance of Biocon shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Biocon's net sales have increased significantly from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025, reflecting a robust growth trend. The total operating income followed a similar pattern, rising from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025. The company's operating profit (PBDIT) also demonstrated a positive trend, climbing from INR 1,538.10 crore in March 2019 to INR 4,374.50 crore in March 2025. However, the operating profit margin has seen a slight decline from 25.27% in March 2019 to 21.04% in March 2025. Profit after tax has increased from INR 1,001.70 crore in March 2019 to INR 1,429.40 crore in March 2025, with a PAT margin of 9.5% in March 2025. On the balance sheet, total assets rose from INR 14,075.80 crore in March 2020 to INR 58,539.60 crore in March 2025, while total liabilities increased from INR 14,075.80 crore to INR 15,860.10 crore over the same period. The cash flow from operating activities improved significantly, reaching INR 4,061.00 crore in March 2025, compared to INR 1,283.00 crore in March 2020. Overall, Biocon has shown strong growth in sales, profits, and cash flow, indicating a solid financial performance over the years.

How has been the historical performance of Biocon?

Biocon has shown consistent growth in net sales and profits, with net sales increasing from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25, and profit after tax rising to 1,429.40 Cr. Total assets grew significantly to 58,539.60 Cr, while total debt also increased, indicating higher financial leverage.

Answer:<BR>The historical performance of Biocon shows a consistent growth trajectory in net sales and profits over the years, with net sales increasing from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25. The total operating income followed a similar trend, rising from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25. Operating profit (PBDIT) also saw a significant increase, reaching 4,374.50 Cr in Mar'25 from 1,538.10 Cr in Mar'19. Profit before tax rose to 1,886.60 Cr in Mar'25, compared to 1,214.00 Cr in Mar'19, while profit after tax increased to 1,429.40 Cr from 1,001.70 Cr in the same period. The earnings per share (EPS) fluctuated, peaking at 8.52 in Mar'24 before slightly declining to 8.44 in Mar'25. The company's total assets grew from 14,075.80 Cr in Mar'20 to 58,539.60 Cr in Mar'25, indicating a robust expansion. However, total debt also increased from 1,154.20 Cr in Mar'20 to 15,860.10 Cr in Mar'25, reflecting a rise in financial leverage. The cash flow from operating activities improved significantly, reaching 4,061.00 Cr in Mar'25, up from 1,283.00 Cr in Mar'20, contributing to a net cash inflow of 2,004.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Biocon's financial performance over the years demonstrates a strong upward trend in both revenue and profitability. Net sales surged from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25, while total operating income mirrored this growth. Operating profit (PBDIT) increased significantly, reaching 4,374.50 Cr in Mar'25, reflecting effective cost management despite rising raw material and employee costs. Profit before tax also saw a notable rise to 1,886.60 Cr in Mar'25, with profit after tax following suit at 1,429.40 Cr. The company's EPS showed variability, peaking at 8.52 in Mar'24 before slightly declining. Total assets expanded dramatically from 14,075.80 Cr in Mar'20 to 58,539.60 Cr in Mar'25, while total debt rose concurrently, indicating increased leverage. Cash flow from operating activities improved significantly, culminating in a net cash inflow of 2,004.00 Cr in Mar'25, showcasing the company's strong operational performance.

Are Biocon latest results good or bad?

Biocon's latest results show a significant quarter-on-quarter net profit increase of 169.11% and revenue growth of 8.97%, indicating strong demand. However, the year-on-year net profit declined sharply by 628.12%, raising concerns about ongoing profitability challenges despite positive revenue trends.

Biocon's latest results present a mixed picture. On one hand, the company reported a significant sequential improvement in net profit, rising by 169.11% quarter-on-quarter to ₹84.50 crores. This is a positive sign, indicating a recovery from the previous quarter's low performance. Additionally, revenue grew by 8.97% quarter-on-quarter and 19.64% year-on-year, reaching ₹4,295.50 crores, which reflects strong demand for its biosimilars and generic products.<BR><BR>However, the year-on-year comparison for net profit shows a substantial decline of 628.12%, down from ₹659.70 crores in the same quarter last year. This sharp drop highlights ongoing profitability challenges, particularly as the previous year's figures were bolstered by significant one-time gains. Furthermore, the company's operating margins, while improved to 19.60%, remain below previous peak levels, indicating pressure on profitability.<BR><BR>Overall, while Biocon's revenue growth is encouraging, the significant decline in net profit year-on-year and the ongoing margin pressures suggest that the results are not entirely positive. Investors may need to weigh the strong revenue growth against the concerns regarding profitability and operational efficiency.

Should I buy, sell or hold Biocon?

Which are the latest news on Biocon?

Why is Biocon falling/rising?

As of 13-Dec, Biocon Ltd.'s stock price is rising to 385.95, reflecting a 1.15% increase. This upward trend is supported by strong performance against its sector, positive moving averages, attractive valuation metrics, and significant institutional holdings, despite a decline in delivery volume.

As of 13-Dec, Biocon Ltd.'s stock price is rising, currently at 385.95, reflecting a change of 4.4 (1.15%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.1% today and has shown consecutive gains over the last two days, with a total return of 1.85% during this period. Additionally, the stock is trading above its 5-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price performance.<BR><BR>Despite a decline in investor participation, as evidenced by a 51.16% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading, which supports its price stability. Furthermore, Biocon's attractive valuation, with a return on capital employed (ROCE) of 4.4 and a low enterprise value to capital employed ratio of 1.7, suggests that it is trading at a discount compared to its peers. This valuation, combined with high institutional holdings at 28.71%, indicates confidence from more knowledgeable investors, which can also contribute to the stock's upward movement.<BR><BR>Overall, while there are some negative indicators, such as a significant drop in profits over the past year, the combination of recent performance, valuation attractiveness, and institutional support appears to be driving the stock's rise.